GRI Bio, Inc. 8-K

What Happened
GRI Bio, Inc. announced in an 8-K filed January 16, 2026 that on January 15, 2026 the Nasdaq Listing Qualifications Staff determined the company has conditionally regained compliance with the stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1). The company had previously been notified of noncompliance based on its Form 10-Q for the quarter ended September 30, 2025 (as disclosed in a December 2, 2025 8-K). The 8-K was signed by CFO Leanne Kelly.

Key Details

• Nasdaq Listing Rule 5550(b)(1) requires listed companies with market value < $35 million and annual net income < $500,000 to maintain at least $2.5 million in stockholders’ equity.
• The company received a noncompliance notice based on its 10-Q for the quarter ended September 30, 2025 (previously reported Dec 2, 2025).
• On January 15, 2026 the Nasdaq Staff determined GRI Bio has conditionally regained compliance.
• The filing notes that if GRI Bio fails to demonstrate continued compliance in future Exchange Act reports, its shares may again be subject to delisting.

Why It Matters
Regaining compliance removes an immediate delisting risk and is positive for continued Nasdaq listing and trading continuity. However, the compliance determination is conditional and depends on future reported results; investors should watch upcoming quarterly and annual filings for sustained stockholders’ equity above the required $2.5 million. Continued noncompliance in future reports could again threaten the company’s listing and affect liquidity and shareholder value.